Extrawell Pharmaceutical Holdings Ltd. Expands Vision to Become Integrated Health Solutions Provider by 2027

Reuters

Sep 10

Extrawell Pharmaceutical Holdings Ltd. Expands Vision to Become Integrated Health Solutions Provider by 2027

Extrawell Pharmaceutical Holdings Ltd. has successfully completed the issuance of 160 million new shares under a general mandate, marking a significant step in its expansion strategy. The company aims to transform into an integrated health solutions provider by leveraging its pharmaceutical expertise and exploring healthcare diversification. The funds raised will support pilot projects through early 2027, with a portion reserved as working capital to scale successful initiatives by the end of 2027. This phased approach is intended to create a balanced and resilient business portfolio, delivering sustainable value to stakeholders by pursuing both domestic and international opportunities. Further updates on developments in this business segment are expected to be announced in due course.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Extrawell Pharmaceutical Holdings Ltd. published the original content used to generate this news brief on September 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2566671595"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566671595\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566671595?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 17:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566671595","market":"fut","top_or_hot":-1,"title":"Extrawell Pharmaceutical Holdings Ltd. Expands Vision to Become Integrated Health Solutions Provider by 2027","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Extrawell Pharmaceutical Holdings Ltd. Expands Vision to Become Integrated Health Solutions Provider by 2027\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Extrawell Pharmaceutical Holdings Ltd. has successfully completed the issuance of 160 million new shares under a general mandate, marking a significant step in its expansion strategy. The company aims to transform into an integrated health solutions provider by leveraging its pharmaceutical expertise and exploring healthcare diversification. The funds raised will support pilot projects through early 2027, with a portion reserved as working capital to scale successful initiatives by the end of 2027. This phased approach is intended to create a balanced and resilient business portfolio, delivering sustainable value to stakeholders by pursuing both domestic and international opportunities. Further updates on developments in this business segment are expected to be announced in due course.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Extrawell Pharmaceutical Holdings Ltd. published the original content used to generate this news brief on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Extrawell Pharmaceutical Holdings Ltd. Expands Vision to Become Integrated Health Solutions Provider by 2027</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExtrawell Pharmaceutical Holdings Ltd. Expands Vision to Become Integrated Health Solutions Provider by 2027\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-10 17:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Extrawell Pharmaceutical Holdings Ltd. Expands Vision to Become Integrated Health Solutions Provider by 2027\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Extrawell Pharmaceutical Holdings Ltd. has successfully completed the issuance of 160 million new shares under a general mandate, marking a significant step in its expansion strategy. The company aims to transform into an integrated health solutions provider by leveraging its pharmaceutical expertise and exploring healthcare diversification. The funds raised will support pilot projects through early 2027, with a portion reserved as working capital to scale successful initiatives by the end of 2027. This phased approach is intended to create a balanced and resilient business portfolio, delivering sustainable value to stakeholders by pursuing both domestic and international opportunities. Further updates on developments in this business segment are expected to be announced in due course.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Extrawell Pharmaceutical Holdings Ltd. published the original content used to generate this news brief on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00858","symbol_name":"精优药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL9d1Y3n:1","article_id":"2566671595","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566671595","pubTimestamp":1757495275,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Extrawell Pharmaceutical Holdings Ltd. has successfully completed the issuance of 160 million new shares under a general mandate, marking a significant step in its expansion strategy. The company aims to transform into an integrated health solutions provider by leveraging its pharmaceutical expertise and exploring healthcare diversification. The funds raised will support pilot projects through early 2027, with a portion reserved as working capital to scale successful initiatives by the end of 2027. This phased approach is intended to create a balanced and resilient business portfolio, delivering sustainable value to stakeholders by pursuing both domestic and international opportunities. Further updates on developments in this business segment are expected to be announced in due course.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00858":"精优药业","BK1191":"制药"},"translate_title":"Extrawell Pharmaceutical Holdings Ltd.扩大愿景，到2027年成为综合健康解决方案提供商","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00858":0.9},"content_text":"Extrawell Pharmaceutical Holdings Ltd. Expands Vision to Become Integrated Health Solutions Provider by 2027\n    \n\n        Extrawell Pharmaceutical Holdings Ltd. has successfully completed the issuance of 160 million new shares under a general mandate, marking a significant step in its expansion strategy. The company aims to transform into an integrated health solutions provider by leveraging its pharmaceutical expertise and exploring healthcare diversification. The funds raised will support pilot projects through early 2027, with a portion reserved as working capital to scale successful initiatives by the end of 2027. This phased approach is intended to create a balanced and resilient business portfolio, delivering sustainable value to stakeholders by pursuing both domestic and international opportunities. Further updates on developments in this business segment are expected to be announced in due course.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Extrawell Pharmaceutical Holdings Ltd. published the original content used to generate this news brief on September 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}